Arvinas ARVN 深 沪
等待开盘 08-25 09:30:00 美东时间
9.34
-0.025
-0.27%
华盛通- 最 高9.39
- 今 开9.28
- 成交量 50.04万股
- 最 低 9.06
- 昨 收 9.365
- 总市值 6.11亿
- 52周最高 14.51
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 6.97
- 委 比 -65.93%
- 总股本 6538.62万
- 历史最高 108.465
- 量 比 0.79
- 振 幅 3.52%
- 历史最低 5.90
- 每 手 1
- 风险率 1.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11
Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weight and lowers the price target from $15 to $11.
08-05 21:44
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Arvinas Holding Earnings Call: PROTAC Milestone and Outlook
Arvinas Holding Company (($ARVN)) has held its Q2 earnings call. Read on for th...
08-05 08:59
Arvinas 2026年第二季度财报：授权收入推动扭亏
Arvinas 2026财年第二季度营收2.497亿美元，稀释EPS为2.58美元，净利润1.694亿美元。VEPPANU获批及授权收入推动扭亏，现有资金预计可支持运营至2028年下半年。
08-05 06:59
BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $18 price target.
08-05 01:45
Arvinas shares are trading higher after the company reported better-than-expected Q2 financial results.
Arvinas shares are trading higher after the company reported better-than-expected Q2 financial results.
08-04 20:50
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate
Arvinas (NASDAQ:ARVN) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $(0.44) by 686.36 percent. This is a 407.14 percent increase over losses of $(0.84) per share from the same period last year. The company reported quarterly sales of $249.700 million whi...
08-04 19:05
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Arvinas, a biotechnology company specializing in targeted protein degradation therapies, will host a live webcast on August 4, 2026, to discuss its second-quarter 2026 financial results and provide a corporate update. The event will be accessible on the company’s investor page, with a replay available post-event. Arvinas is pioneering PROTAC-based protein degraders, including the first FDA-approved PROTAC, and is advancing multiple investigationa...
07-28 11:00
